Sartorius integrates online biomass measurement to its ambr systems for microbial applications
Scientists to rapidly obtain detailed process understanding and control over their microbial cultures.
Sartorius Stedim Biotech (SSB) is introducing integrated online biomass measurement to its ambr 15 fermentation and ambr 250 high throughput systems for microbial applications.
Already well known in the industry for fast-tracking microbial screening studies and shortening process development timelines, the ambr 15 fermentation and ambr 250 high throughput systems operate up to 24 single-use stirred bioreactor cultures in parallel. With the integration of online biomass measurement, SSB has addressed the bottleneck associated with offline sampling. The new online biomass capability features state-of-the-art non-invasive reflectance measurement, saving time, effort and sample volume. It enables scientists to rapidly obtain detailed process understanding and control over their microbial cultures.
Online biomass measurement provides real-time non-invasive, continuous growth monitoring of 24 microbial cultures running in parallel. The reflectance-based technology means that sampling is not required. Instead, it uses lasers to transmit light through the base of each bioreactor and microprocessors to translate this into a reflectance measurement. With a wide dynamic measurement range, and bubble correction factors to take into account gas bubble density, reliable online measurements can be achieved even in high aeration and agitation environments. Through a user calibration process, online reflectance can be displayed as online optical density (OD), wet cell weight (WCW) or dry cell weight (DCW). To date, the online biomass measurement has been successfully tested with different organisms including E.coli, Pichia pastoris, Saccharomyces cerevisiae, Streptomyces spp. and Corynebacterium spp.
“Fermentation scientists often have to perform time-consuming sampling to monitor growth and initiate process control based on offline data. Sample preparation and manual data handling can introduce variability and errors; it may also necessitate samples being taken at unsociable hours or over weekends,” explained Alison Rees-Manley, ambr 15 Product Manager at SSB. “By integrating innovative biomass monitoring technology into our ambr systems for microbial applications, we enable real-time growth data to be used for more advanced process control. We’re confident that these ambr systems will help scientists by reducing the burden of offline sampling and providing better process understanding and greater control of microbial cultures. This will result in more accurate and predictive data for cost-efficient protein production,” she added.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...